11481 RESULTS
COMMENT I think it makes sense to concentrate on biomarker endpoints, but that doesn’t necessarily imply ignoring cognitive endpoints perpetually. Ultimately, that’s where the rubber meets the road! A broader point is that the Aβ immunotherapies are a relatively
COMMENT Let me add the perspective of a clinical trial participant. I entered a study of a mAb drug not knowing that having an APOE4 gene and a brain full of amyloid plaque would put me at higher risk for ARIA. I thought, being relatively young (65) and healthy,
COMMENT This is an extremely important discussion. I am homozygous for ApoE4, asymptomatic, a 15-year research participant in a longitudinal biomarker study, a research and AD advocate, and author of an award-winning book published by Harper-Collins of knowing my
COMMENT Aging is associated with many ailments such as cardiovascular, cancer, and neurodegenerative diseases. In this article, the authors focus on the aging brain, specifically, and how the difference between biologic aging and chronologic aging of the brain, d
COMMENT This interesting study provides valuable insights into plasma proteomic changes associated with the brain age gap (BAG), highlighting brevican and GDF-15 as markers of brain aging physiology manifesting in multimodal structural brain imaging. As described
COMMENT This new study by Liu et al. provides a clear and compelling example of how plasma proteomics can be leveraged to identify novel targets for brain disorders. Using U.K. Biobank data from nearly 11,000 individuals, the authors developed a multimodal brain-
COMMENT I commend the authors for their multimodal imaging approach to brain age estimation. Making use of 1705 imaging-derived phenotypes as parameters for estimating brain age, this study used information from T1- and T2-weighted structural MRI, functional MRI,
COMMENT In this study, Western et al. leveraged CSF-based proteomics via the SOMAscan 7k platform and genetic data from approximately 3,500 individuals to conduct the largest investigation of CSF protein quantitative trait loci (pQTLs) to date. This study provide
COMMENT This study presents a comprehensive analysis of transcriptomic changes in astrocytes across different parts of the neural network vulnerable to Alzheimer’s disease. Using single-nucleus RNA sequencing, the authors analyzed 628,943 astrocytes from 32 donor
COMMENT The work led by Swarup, Miyoshi, and Head is a tour de force and a valuable contribution of incredibly rich datasets to the field. The design is strong with comparisons between early stage AD and late-stage AD and Down’s syndrome to derive shared and spec
COMMENT I think the proposal by Aisen and colleagues for approval of antibodies that remove Aβ based solely on imaging and supportive biomarker evidence is premature. While there is evidence from interventional and observational studies in support of an “amyloid
COMMENT The International Working Group has long contributed to refining the definition and diagnosis of Alzheimer’s disease (Dubois et al., 2007, 2024). Among its many efforts, two contributions remain essential: 1) In clinical practice, AD should be diagnosed o
COMMENT The authors present a case for accelerated regulatory approval of amyloid-lowering immunotherapies. Given current data in the field from anti-amyloid immunotherapies, they make several key points regarding anti-amyloid antibodies: Evidence of robust amylo
COMMENT The authors state that lowering amyloid plaques, or attenuating their increase compared to placebo, should be considered a surrogate clinical outcome or marker for clinical trials of amyloid-lowering treatments. Specifically, for trials of amyloid-targeti
COMMENT In this article, Aisen et al. argue that if new amyloid lowering immunotherapies (ALIs) were to come before the FDA with “clear-cut biomarker evidence” of amyloid lowering and acceptable safety profiles, approval should be granted prior to availability of
